FBInvestor
Stocks / Syndax Pharmaceuticals Inc
Institutional Ownership

Syndax Pharmaceuticals Inc

CUSIP 87164F105COMSNDXQ1 2026

13D / 13G Filings
63
Schedule 13D/13G on record
Beneficial Filers
22
Distinct reporting persons
Largest Stake
11.7%
Max % of class reported
Institutional Holders
237
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

63 filings · latest Feb 9, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 9, 2026State Street Corporation13G5.3%4.60MSEC
2Jan 30, 2026The Vanguard Group13G/A7.2%6.23MSEC
3Aug 18, 2025Point72 Asset Management, L.P.13G5.0%4.33MSEC
4Aug 14, 2025Point72 Asset Management, L.P.13G/A2.7%2.31MSEC
5Aug 13, 2025The Goldman Sachs Group, Inc.13G/A11.0%5.58MSEC
6May 9, 2025The Goldman Sachs Group, Inc.13G/A11.0%4.51MSEC
7May 7, 2025Morgan Stanley13G/A2.4%2.04MSEC
8Apr 17, 2025Blackrock, Inc.13G/A7.8%6.74MSEC
9Mar 7, 2025Wellington Management Group LLP13G/A0.0%35.7KSEC
10Feb 14, 2025Kynam Capital Management, LP13G/A10.0%8.52MSEC

53 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Syndax Pharmaceuticals Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →